Magnetic resonance spectroscopy in affective disorders

J Neuropsychiatry Clin Neurosci. Spring 1998;10(2):133-47. doi: 10.1176/jnp.10.2.133.

Abstract

Magnetic resonance spectroscopy (MRS) is a non-invasive tool for in vivo chemical analysis that has been applied to neurobiological or psychopharmacological studies of affective disorders. Studies employing 31P-MRS and 1H-MRS have indicated possible abnormalities in membrane phospholipid metabolism, high-energy phosphate metabolism, and intracellular pH in affective disorders. They have also suggested that lithium increases the phosphomonoester (possibly inositol-1-phosphate) peak in the brain but does not increase that of choline-containing compounds in the brain. Studies employing 7Li-MRS and 19F-MRS have elucidated the pharmacokinetic properties of lithium, fluoxetine, and fluvoxamine in the brain in patients treated with these drugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Affect / physiology
  • Animals
  • Antidepressive Agents, Second-Generation / pharmacokinetics
  • Antipsychotic Agents / pharmacology
  • Basal Ganglia / drug effects
  • Basal Ganglia / metabolism
  • Bipolar Disorder / drug therapy
  • Bipolar Disorder / physiopathology
  • Brain Chemistry* / drug effects
  • Depression / drug therapy
  • Depression / physiopathology
  • Energy Metabolism
  • Fluorine Radioisotopes / pharmacokinetics
  • Frontal Lobe / drug effects
  • Frontal Lobe / metabolism
  • Humans
  • Hydrogen
  • Lithium / pharmacology
  • Magnetic Resonance Spectroscopy* / methods
  • Membrane Lipids / metabolism
  • Mood Disorders / drug therapy
  • Mood Disorders / physiopathology*
  • Phosphorus Radioisotopes
  • Radioisotopes / pharmacokinetics

Substances

  • Antidepressive Agents, Second-Generation
  • Antipsychotic Agents
  • Fluorine Radioisotopes
  • Membrane Lipids
  • Phosphorus Radioisotopes
  • Radioisotopes
  • Hydrogen
  • Lithium